chr7-117611622-G-C

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong

The NM_000492.4(CFTR):​c.3181G>C​(p.Gly1061Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,613,334 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

CFTR
NM_000492.4 missense

Scores

18
1

Clinical Significance

Pathogenic reviewed by expert panel P:11

Conservation

PhyloP100: 9.94
Variant links:
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 14 ACMG points.

PM1
In a topological_domain Cytoplasmic (size 60) in uniprot entity CFTR_HUMAN there are 21 pathogenic changes around while only 1 benign (95%) in NM_000492.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.927
PP5
Variant 7-117611622-G-C is Pathogenic according to our data. Variant chr7-117611622-G-C is described in ClinVar as [Pathogenic]. Clinvar id is 53672.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr7-117611622-G-C is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
CFTRNM_000492.4 linkuse as main transcriptc.3181G>C p.Gly1061Arg missense_variant 20/27 ENST00000003084.11 NP_000483.3 P13569-1A0A024R730

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
CFTRENST00000003084.11 linkuse as main transcriptc.3181G>C p.Gly1061Arg missense_variant 20/271 NM_000492.4 ENSP00000003084.6 P13569-1

Frequencies

GnomAD3 genomes
AF:
0.00000658
AC:
1
AN:
152058
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000399
AC:
1
AN:
250828
Hom.:
0
AF XY:
0.00
AC XY:
0
AN XY:
135556
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000882
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000137
AC:
2
AN:
1461158
Hom.:
0
Cov.:
30
AF XY:
0.00000138
AC XY:
1
AN XY:
726878
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000180
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152176
Hom.:
0
Cov.:
31
AF XY:
0.0000134
AC XY:
1
AN XY:
74398
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000147
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.00000756
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000116
AC:
1

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:11
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Cystic fibrosis Pathogenic:6
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJan 27, 2023The p.G1061R pathogenic mutation (also known as c.3181G>C and c.3313G>C), located in coding exon 20 of the CFTR gene, results from a G to C substitution at nucleotide position 3181. The glycine at codon 1061 is replaced by arginine, an amino acid with dissimilar properties. This variant has been confirmed in trans and identified likely in trans with a CFTR pathogenic variant in multiple individuals with clinical features of cystic fibrosis and CFTR-related disorders including, but not limited to: elevated sweat chloride levels, pulmonary disease, and pancreatic insufficiency (Bienvenu T et al. Hum Mutat, 1996;7:376-7; Mercier B et al. Genomics, 1993 Apr;16:296-7; Ravnik-Glavac M et al. Hum Mutat, 2002 Apr;19:374-83; Sala MA et al. J Cyst Fibros, 2021 Mar;20:356-363; Ambry internal data). In one functional study, this mutation was observed to result in protein misprocessing and failure of protein maturation (Seibert FS et al. J Biol Chem. 1996;271(25):15139-45). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpNov 22, 2019Variant summary: CFTR c.3181G>C (p.Gly1061Arg) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250828 control chromosomes (gnomAD). c.3181G>C has been reported in the literature in individuals affected with Cystic Fibrosis (e.g. Alper_2004, Bienvenu_1995, Chertkoff_1997, Mercier_1993). These data indicate that the variant is likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated the variant to cause misprocessing and failure of maturation of CFTR resulting in its retention in the endoplasmic reticulum (Seibert_1996). Three ClinVar submitters including an expert panel (CFTR2) (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpMay 13, 2022This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1061 of the CFTR protein (p.Gly1061Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with cystic fibrosis (PMID: 7683628, 8723695, 9084934; The Clinical and Functional TRanslation of CFTR (CFTR2) at http://cftr2.org). ClinVar contains an entry for this variant (Variation ID: 53672). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CFTR function (PMID: 8662892). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingJohns Hopkins Genomics, Johns Hopkins UniversityFeb 15, 2021- -
Pathogenic, reviewed by expert panelresearchCFTR2Mar 17, 2017- -
Pathogenic, criteria provided, single submittercurationCFTR-FranceJan 29, 2018- -
not specified Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesFeb 02, 2019The CFTR c.3181G>C, p.Gly1061Arg variant has been reported in cystic fibrosis patients (Alper 2004, Mercier 1993, Visich 2002, SickKids CFTR database, CFTR2 database), with variable presentation of pancreatic insufficiency (CFTR2 database). Functional characterization of the variant protein indicates that chloride conductance is severely impaired (CFTR2 database). The variant is listed in the ClinVar database (Variation ID: 53672), in the dbSNP variant database (rs142394380), and observed in the general population databases at a frequency of 0.02 percent in the 1000 Genomes Project, and 0.0077 percent in the Exome Variant Server. The glycine at residue 1061 is highly conserved, and computational algorithms (Align GV/GD, Mutation Taster, PolyPhen-2, SIFT) predict that the variant has an impact on the protein. Based on the above information, the variant is classified as moderately pathogenic. References: CFTR2 database: https://cftr2.org/ Link to p.Gly1061Arg in SickKids database: http://www.genet.sickkids.on.ca/cftr/MutationDetailPage.external?sp=443 Alper OM et al. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat. 2004 Oct;24(4):353. Mercier B et al. Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. Genomics. 1993 16(1):296-7. Visich A et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. Clin Genet. 2002 Mar;61(3):207-13. -
CFTR-related disorder Pathogenic:1
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Aug 28, 2017- -
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor Genetics-- -
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Mar 02, 2018- -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsJan 30, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.99
BayesDel_addAF
Pathogenic
0.52
D
BayesDel_noAF
Pathogenic
0.50
CADD
Pathogenic
32
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.92
D;.;.;D;.
Eigen
Pathogenic
0.83
Eigen_PC
Pathogenic
0.84
FATHMM_MKL
Pathogenic
1.0
D
LIST_S2
Pathogenic
0.99
D;D;D;D;D
M_CAP
Pathogenic
0.88
D
MetaRNN
Pathogenic
0.93
D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
4.3
H;.;.;.;.
PrimateAI
Pathogenic
0.93
D
PROVEAN
Pathogenic
-6.6
D;.;.;D;.
REVEL
Pathogenic
0.95
Sift
Pathogenic
0.0
D;.;.;D;.
Sift4G
Pathogenic
0.0
D;.;.;D;.
Polyphen
1.0
D;.;.;.;.
Vest4
1.0
MutPred
0.97
Gain of MoRF binding (P = 0.0163);.;.;.;.;
MVP
0.99
MPC
0.016
ClinPred
1.0
D
GERP RS
5.7
Varity_R
0.99
gMVP
1.0

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs142394380; hg19: chr7-117251676; API